- Home
- BEAM vs RXST Comparison
BEAM vs RXST Comparison
Compare BEAM & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- RXST
- Stock Information
- Founded
- BEAM 2017
- RXST 1997
- Country
- BEAM United States
- RXST United States
- Employees
- BEAM N/A
- RXST N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- BEAM Health Care
- RXST Health Care
- Exchange
- BEAM Nasdaq
- RXST Nasdaq
- Market Cap
- BEAM 1.6B
- RXST 553.1M
- IPO Year
- BEAM 2020
- RXST 2021
- Fundamental
- Price
- BEAM $17.23
- RXST $13.00
- Analyst Decision
- BEAM Strong Buy
- RXST Buy
- Analyst Count
- BEAM 11
- RXST 10
- Target Price
- BEAM $48.90
- RXST $39.30
- AVG Volume (30 Days)
- BEAM 1.9M
- RXST 607.8K
- Earning Date
- BEAM 08-05-2025
- RXST 08-04-2025
- Dividend Yield
- BEAM N/A
- RXST N/A
- EPS Growth
- BEAM N/A
- RXST N/A
- EPS
- BEAM N/A
- RXST N/A
- Revenue
- BEAM $63,578,000.00
- RXST $148,310,000.00
- Revenue This Year
- BEAM N/A
- RXST $22.16
- Revenue Next Year
- BEAM $8.82
- RXST $20.91
- P/E Ratio
- BEAM N/A
- RXST N/A
- Revenue Growth
- BEAM N/A
- RXST 46.70
- 52 Week Low
- BEAM $13.53
- RXST $12.53
- 52 Week High
- BEAM $35.25
- RXST $59.67
- Technical
- Relative Strength Index (RSI)
- BEAM 48.68
- RXST 36.85
- Support Level
- BEAM $16.11
- RXST $12.60
- Resistance Level
- BEAM $17.38
- RXST $14.25
- Average True Range (ATR)
- BEAM 1.02
- RXST 0.72
- MACD
- BEAM 0.03
- RXST -0.12
- Stochastic Oscillator
- BEAM 30.84
- RXST 11.76
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.